Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RB-ADSC

Phase 2Cell therapy

RRegeneration Biomedical, Inc.

RB-ADSC is one of 46 biologic programs targeting Alzheimer disease. It is currently in Phase 2.

2

Indications

3

Total Trials

3

Active Trials

45

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer DiseaseNot yet recruiting

Mild to Moderate Alzheimer's DiseaseRecruiting

Alzheimer DiseasePhase 2

Not yet recruiting

Mild to Moderate Alzheimer's DiseasePhase 1

Recruiting

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Leqembi

Dayvigo

Epidiolex

Jazz Pharmaceuticals

Avandia

Jazz Pharmaceuticals

Estrace

Aleve

Jazz Pharmaceuticals

Cialis

Rifadin

Avelox

Victoza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Alzheimer Disease

NCT07373067

Q1 2030

Phase 2Not yet recruiting

Alzheimer Disease

NCT07205601

Clinical

Trials by Indication[1]

Alzheimer disease2 trials

A Phase 1b Extension Trial To Allow Repeat Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Subjects Previously Treated in RBI Protocol RB-ADSC-02

Not yet recruiting·RRegeneration Biomedical, Inc.·Phase 1·NCT07373067·9 enrolled

Phase 2a Assessment of Safety, Tolerability, and Efficacy of Repeated Dosing of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (RB-ADSCs) in Participants With Mild to Moderate Alzheimer's Disease

Not yet recruiting·RRegeneration Biomedical, Inc.·Phase 2·NCT07205601·115 enrolled

Mild to Moderate Alzheimer's Disease1 trial

Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

Recruiting·RRegeneration Biomedical, Inc.·Phase 1·NCT05667649·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for RB-ADSC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RB-ADSC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RB-ADSC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneration Biomedical, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: RRegeneration Biomedical, Inc.

Related News